Genelux Corporation (GNLX)

Market Cap	127.94M
Revenue (ttm)	n/a
Net Income (ttm)	-29.51M
Shares Out	37.30M
EPS (ttm)	-0.88
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	127,340
Open	3.300
Previous Close	3.440
Day's Range	3.300 - 3.470
52-Week Range	1.600 - 5.885
Beta	-0.37
Analysts	Strong Buy
Price Target	17.75 (+419.01%)
Earnings Date	Aug 13, 2025

About GNLX

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer and non-small cell lung cancer, as well as for liquid or solid tumors, appendiceal, colorectal and gastric cancers, other gynecologic malignancies, and peritoneal mesothelioma. The company has a licensing agre...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 26, 2023
• Employees: 24
• Stock Exchange: NASDAQ
• Ticker Symbol: GNLX
• Website: https://www.genelux.com

Financial Performance

In 2024, Genelux's revenue was $8,000, a decrease of -95.29% compared to the previous year's $170,000. Losses were -$29.87 million, 5.56% more than in 2023.

Analyst Summary

According to 4 analysts, the average rating for GNLX stock is "Strong Buy." The 12-month stock price target is $17.75, which is an increase of 419.01% from the latest price.

Price Target

$17.75

(419.01% upside)

Analyst Consensus: Strong Buy